

# JosÃ© A Melero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1508531/publications.pdf>

Version: 2024-02-01

61  
papers

4,421  
citations

101535

36  
h-index

123420

61  
g-index

63  
all docs

63  
docs citations

63  
times ranked

4501  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric <i>Pneumoviridae</i> fusion proteins as immunogens to induce crossâ neutralizing antibody responses. EMBO Molecular Medicine, 2018, 10, 175-187.	6.9	10
2	Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine, 2018, 36, 6660-6673.	3.8	32
3	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
4	Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nature Communications, 2017, 8, 14158.	12.8	58
5	Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nature Communications, 2017, 8, 1528.	12.8	86
6	Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development. Vaccine, 2017, 35, 461-468.	3.8	53
7	The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years. Frontiers in Microbiology, 2017, 8, 2301.	3.5	13
8	Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Science Immunology, 2016, 1, .	11.9	180
9	Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development. Expert Review of Vaccines, 2016, 15, 1319-1325.	4.4	4
10	Trivalency of a Nanobody Specific for the Human Respiratory Syncytial Virus Fusion Glycoprotein Drastically Enhances Virus Neutralization and Impacts Escape Mutant Selection. Antimicrobial Agents and Chemotherapy, 2016, 60, 6498-6509.	3.2	30
11	ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation. Journal of Virology, 2016, 90, 3428-3438.	3.4	56
12	Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. Journal of Virology, 2016, 90, 5485-5498.	3.4	29
13	Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 6-13.	3.2	222
14	Engineering, Structure and Immunogenicity of the Human Metapneumovirus F Protein in the Postfusion Conformation. PLoS Pathogens, 2016, 12, e1005859.	4.7	50
15	Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathogens, 2015, 11, e1005035.	4.7	106
16	Conservation of G-Protein Epitopes in Respiratory Syncytial Virus (Group A) Despite Broad Genetic Diversity: Is Antibody Selection Involved in Virus Evolution?. Journal of Virology, 2015, 89, 7776-7785.	3.4	62
17	Clinical response to pandemic h1n1 influenza virus from a fatal and mild case in ferrets. Virology Journal, 2015, 12, 48.	3.4	8
18	The Pneumovirinae fusion (F) protein: A common target for vaccines and antivirals. Virus Research, 2015, 209, 128-135.	2.2	26

#	ARTICLE	IF	CITATIONS
19	Generation of monoclonal antibodies specific of the postfusion conformation of the Pneumovirinae fusion (F) protein. <i>Journal of Virological Methods</i> , 2015, 224, 1-8.	2.1	7
20	Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics. <i>PLoS ONE</i> , 2015, 10, e0130829.	2.5	15
21	Social, economic, and health impact of the respiratory syncytial virus: a systematic search. <i>BMC Infectious Diseases</i> , 2014, 14, 544.	2.9	76
22	Characterization of an enhanced antigenic change in the pandemic 2009 H1N1 influenza virus haemagglutinin. <i>Journal of General Virology</i> , 2014, 95, 1033-1042.	2.9	10
23	A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes. <i>Journal of Virology</i> , 2014, 88, 11802-11810.	3.4	38
24	Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation. <i>Virology</i> , 2014, 460-461, 119-127.	2.4	11
25	Influence of Respiratory Syncytial Virus Strain Differences on Pathogenesis and Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 59-82.	1.1	51
26	Characterization In Vitro and In Vivo of a Pandemic H1N1 Influenza Virus from a Fatal Case. <i>PLoS ONE</i> , 2013, 8, e53515.	2.5	29
27	Entry of Enveloped Viruses into Host Cells: Membrane Fusion. <i>Sub-Cellular Biochemistry</i> , 2013, 68, 467-487.	2.4	50
28	Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3089-3094.	7.1	217
29	Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein. <i>Archives of Virology</i> , 2012, 157, 1071-1080.	2.1	7
30	Llama-Derived Single Domain Antibodies to Build Multivalent, Superpotent and Broadened Neutralizing Anti-Viral Molecules. <i>PLoS ONE</i> , 2011, 6, e17665.	2.5	150
31	Progress in understanding and controlling respiratory syncytial virus: Still crazy after all these years. <i>Virus Research</i> , 2011, 162, 80-99.	2.2	381
32	Residues of the Human Metapneumovirus Fusion (F) Protein Critical for Its Strain-Related Fusion Phenotype: Implications for the Virus Replication Cycle. <i>Journal of Virology</i> , 2011, 85, 12650-12661.	3.4	22
33	Recombinant Sendai Viruses Expressing Fusion Proteins with Two Furin Cleavage Sites Mimic the Syncytial and Receptor-Independent Infection Properties of Respiratory Syncytial Virus. <i>Journal of Virology</i> , 2011, 85, 2771-2780.	3.4	30
34	Neutralization of Human Respiratory Syncytial Virus Infectivity by Antibodies and Low-Molecular-Weight Compounds Targeted against the Fusion Glycoprotein. <i>Journal of Virology</i> , 2010, 84, 7970-7982.	3.4	54
35	Ten Years of Global Evolution of the Human Respiratory Syncytial Virus BA Genotype with a 60-Nucleotide Duplication in the G Protein Gene. <i>Journal of Virology</i> , 2010, 84, 7500-7512.	3.4	153
36	Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. <i>Nature Medicine</i> , 2009, 15, 34-41.	30.7	430

#	ARTICLE	IF	CITATIONS
37	Structural properties of the human respiratory syncytial virus P protein: Evidence for an elongated homotetrameric molecule that is the smallest orthologue within the family of paramyxovirus polymerase cofactors. <i>Proteins: Structure, Function and Bioinformatics</i> , 2008, 72, 946-958.	2.6	43
38	Low-pH-Induced Membrane Fusion Mediated by Human Metapneumovirus F Protein Is a Rare, Strain-Dependent Phenomenon. <i>Journal of Virology</i> , 2008, 82, 8891-8895.	3.4	65
39	Insertion of the Two Cleavage Sites of the Respiratory Syncytial Virus Fusion Protein in Sendai Virus Fusion Protein Leads to Enhanced Cell-Cell Fusion and a Decreased Dependency on the HN Attachment Protein for Activity. <i>Journal of Virology</i> , 2008, 82, 5986-5998.	3.4	27
40	Characterization of the epitope for anti-human respiratory syncytial virus F protein monoclonal antibody 101F using synthetic peptides and genetic approaches. <i>Journal of General Virology</i> , 2007, 88, 2719-2723.	2.9	48
41	Structural analysis of the human respiratory syncytial virus phosphoprotein: characterization of an $\alpha$ -helical domain involved in oligomerization. <i>Journal of General Virology</i> , 2006, 87, 159-169.	2.9	65
42	Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity. <i>Journal of General Virology</i> , 2006, 87, 1649-1658.	2.9	15
43	Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation. <i>Journal of Medical Virology</i> , 2005, 76, 248-255.	5.0	25
44	The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 8996-9001.	7.1	101
45	Genetic and Antigenic Variability of Human Respiratory Syncytial Virus (Groups A and B) Isolated over Seven Consecutive Seasons in Argentina (1995 to 2001). <i>Journal of Clinical Microbiology</i> , 2005, 43, 2266-2273.	3.9	45
46	Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism. <i>Journal of General Virology</i> , 2004, 85, 3677-3687.	2.9	33
47	The Soluble Form of Human Respiratory Syncytial Virus Attachment Protein Differs from the Membrane-Bound Form in Its Oligomeric State but Is Still Capable of Binding to Cell Surface Proteoglycans. <i>Journal of Virology</i> , 2004, 78, 3524-3532.	3.4	45
48	Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities. <i>Vaccine</i> , 2004, 23, 435-443.	3.8	10
49	Effect of Proteolytic Processing at Two Distinct Sites on Shape and Aggregation of an Anchorless Fusion Protein of Human Respiratory Syncytial Virus and Fate of the Intervening Segment. <i>Virology</i> , 2002, 298, 317-326.	2.4	66
50	Evaluation of the antibody specificities of human convalescent-phase sera against the attachment (G) protein of human respiratory syncytial virus: Influence of strain variation and carbohydrate side chains. <i>Journal of Medical Virology</i> , 2000, 60, 468-474.	5.0	65
51	Electron Microscopy of the Human Respiratory Syncytial Virus Fusion Protein and Complexes That It Forms with Monoclonal Antibodies. <i>Virology</i> , 2000, 271, 122-131.	2.4	101
52	DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. <i>Journal of General Virology</i> , 2000, 81, 2519-2523.	2.9	51
53	Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. <i>Journal of General Virology</i> , 2000, 81, 2715-2722.	2.9	91
54	The C-terminal third of human respiratory syncytial virus attachment (G) protein is partially resistant to protease digestion and is glycosylated in a cell-type-specific manner. <i>Journal of General Virology</i> , 2000, 81, 919-927.	2.9	20

#	ARTICLE	IF	CITATIONS
55	Priming with a Secreted Form of the Fusion Protein of Respiratory Syncytial Virus (RSV) Promotes Interleukin-4 (IL-4) and IL-5 Production but Not Pulmonary Eosinophilia following RSV Challenge. Journal of Virology, 1999, 73, 10086-10094.	3.4	40
56	Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia. Journal of Experimental Medicine, 1998, 187, 1921-1926.	8.5	137
57	Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein. Biopolymers, 1998, 39, 537-548.	2.4	15
58	Recombinant Vaccinia Virus Coexpressing the F Protein of Respiratory Syncytial Virus (RSV) and Interleukin-4 (IL-4) Does Not Inhibit the Development of RSV-Specific Memory Cytotoxic T Lymphocytes, whereas Priming Is Diminished in the Presence of High Levels of IL-2 or Gamma Interferon. Journal of Virology, 1998, 72, 4080-4087.	3.4	55
59	Membrane Permeability Changes Induced in Escherichia coli by the SH Protein of Human Respiratory Syncytial Virus. Virology, 1997, 235, 342-351.	2.4	66
60	Host Cell Effect upon Glycosylation and Antigenicity of Human Respiratory Syncytial Virus G Glycoprotein. Virology, 1996, 221, 301-309.	2.4	66
61	Mapping of Monoclonal Antibody Epitopes of the Human Respiratory Syncytial Virus P Protein. Virology, 1993, 195, 239-242.	2.4	14